Edwards received additional information through follow up with the healthcare provider that the reason for the valve explant was due to severe aortic regurgitation due to right coronary leaflet tear.The patient underwent redo sternotomy, avr with 25 mm pericardial aortic valve, mitral valve plasty with 34 mm annuloplasty ring, biatrial maze, and atriclip.There were no complications and the patient was transferred to the cticu in stable condition.
|
Evaluation summary: x-ray demonstrated heavy calcification on leaflet 1, moderate calcification on leaflet 3, and wireform intact.As received, the sewing ring was cut off around the valve and exposed the wireform.Both bands were removed and not returned.Leaflet 1 had two tears of 5mm near commissure 1, and 6mm near commissure 2.Leaflet 2 had a 3mm tear near commissure 2.Leaflet 3 had a tear of 4mm near commissure 3, and a 3mm non-transmural tear at the inflow aspect near commissure 1.Calcification was evident near the tears on leaflet 1, and on leaflet 3 near commissure 3.Tissue thickening and swelling was also observed on the leaflets near the commissures.Additional manufacturer narrative: calcification is a well-recognized failure mode of bioprosthetic valves.Many factors can contribute to the onset and propagation of calcification including patient related (e.G.Patient age, disease state, immune status, and other co-morbidities), pharmacological, and intrinsic properties of the valve itself.It is widely understood that patients with chronic renal disease and prior history of calcific stenosis of the native valve may be predisposed to bioprosthetic calcification.Though numerous studies have been conducted on preventive calcification strategies in bioprosthetic heart valves, the causes of calcification are not fully understood and there are still no mechanisms or medical therapies which fully prevent bioprostheses from calcifying.Based on the product evaluation, the root cause for the calcification remains indeterminable.However, it is likely that patient related factors and the progression of the underlying valvular disease pathology contributed to the event.The device history record (dhr) was reviewed and showed that this device met all manufacturing and sterilization specifications for product release prior to distribution.No issues were identified that would have impacted this event.Edwards will continue to review and monitor all events.Trends are monitored on a monthly basis and if action is required, appropriate investigation will be performed.
|